SillaJen, Inc. (KOSDAQ:215600)
South Korea · Delayed Price · Currency is KRW 2,480.00
-95.00 (-3.69%)
Sep 1, 2026, 3:30 PM KST
SillaJen Revenue
SillaJen had revenue of 2.85B KRW in the quarter ending March 31, 2026, with 146.45% growth. This brings the company's revenue in the last twelve months to 10.92B, up 128.38% year-over-year. In the year 2025, SillaJen had annual revenue of 9.23B with 134.94% growth.
Revenue (ttm)
10.92B
Revenue Growth
+128.38%
P/S Ratio
32.67
Revenue / Employee
191.58M
Employees
57
Market Cap
356.78B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.23B | 5.30B | 134.94% |
| Dec 31, 2024 | 3.93B | -12.90M | -0.33% |
| Dec 31, 2023 | 3.94B | -1.07B | -21.42% |
| Dec 31, 2022 | 5.01B | 4.76B | 1,870.95% |
| Dec 31, 2021 | 254.36M | -1.42B | -84.77% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GC Corp. | 2.49T |
| Bioneer | 338.01B |
| Medy-Tox | 251.08B |
| GC Cell | 162.00B |
| MEDIPOST | 74.84B |
| GI Innovation | 5.63B |
| AbClon | 5.31B |
| Hyundai Bioscience | 3.32B |